REVVITY, INC. Annual Report - A Deep Dive for Investors

For investors considering REVVITY, INC., this guide offers a clear, investor-focused summary of the company's performance and strategic developments for the fiscal year ending December 31, 2025, compared to the prior year. We translate key insights from their annual report into plain English, helping you understand the company's trajectory and evaluate its potential fit for your portfolio.

---

1. Business Overview (what the company does)

REVVITY, INC. specializes in the Life Sciences and Diagnostics sectors. They provide essential tools, technologies, and services that support scientific research, clinical diagnostics, and laboratory operations. The company sharpened its focus by divesting its "Analytical, Food, and Enterprise Services Businesses" in March 2023. This strategic move streamlined operations and concentrated resources on higher-growth, higher-margin core segments. Operating globally, REVVITY serves pharmaceutical companies, biotechnology firms, academic and research institutions, and clinical laboratories.

2. Financial Performance (revenue, profit, year-over-year changes)

Investors typically look to key financial figures to understand a company's health. One notable financial development was a 6.9% reduction in shares outstanding, decreasing from approximately 120.6 million at the end of fiscal year 2024 to 112.3 million at the end of fiscal year 2025. This reduction typically signals a share buyback program. A lower share count can benefit investors by increasing each remaining share's ownership stake in the company's earnings and assets, potentially boosting EPS if net income remains stable or grows.

3. Management Discussion and Analysis (MD&A) Highlights

The MD&A section offers management's insights into the company's financial condition and operational results.

• Operational Highlights: A key strategic highlight for REVVITY, INC. was the divestiture of its Analytical, Food, and Enterprise Services Businesses in March 2023. Although this occurred in the prior fiscal year, it profoundly shaped the company's operations and financial profile for fiscal year 2025. This move enabled the company to focus resources, streamline operations, and potentially improve margins by concentrating on its core, higher-growth Life Sciences and Diagnostics segments.
• Liquidity and Capital Resources: Discussions regarding liquidity and capital resources, including the company's ability to fund operations and investments, are detailed further in the 'Financial Health' section below.

4. Financial Health (debt, cash, liquidity)

REVVITY, INC. carries a significant debt load on its balance sheet. At the end of fiscal year 2025, total debt increased slightly to approximately $4.3 billion, up from $4.0 billion at year-end 2024. This increase primarily stems from reclassifying $300 million of their 1.875% notes due in 2026 as short-term debt, as they mature within the next year. The total amount of their longer-term loans remained stable at $4.0 billion.

Their debt structure includes:

• $300 million in notes due in 2026 (now short-term)
• $500 million in notes due in 2028
• $600 million in notes due in 2029
• $700 million in notes due in 2031
• $800 million in notes also due in 2031
• $900 million in notes due in 2051

Regarding liquidity, the company maintains a strong safety net: an available line of credit extending until January 2030, which it has not yet utilized. This provides access to additional funds, enhancing financial flexibility.

Furthermore, the company's employee pension plans show improved health. Assets for these plans grew from $950 million at year-end 2024 to $1 billion at year-end 2025. This indicates better funding of long-term employee obligations, reducing potential future liabilities for the company.

---

This summary provides key insights, but always remember to conduct your own thorough due diligence before making any investment decisions.